Neostigmine methyl sulfate , 98% , 51-60-5

Synonym(s):
3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate

CAS NO.：51-60-5

Empirical Formula: C12H19N2O2.CH3O4S

Molecular Weight: 334.39

MDL number: MFCD00011796

EINECS: 200-109-5

PRODUCT Properties

• Melting point: 175-177 °C(lit.)
• storage temp.: -20°C
• solubility: H₂O: 1 g/mL
• form: powder
• color: white
• Water Solubility: 1g/10mL
• Merck: 14,6464
• InChI: InChI=1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1
• InChIKey: OSZNNLWOYWAHSS-UHFFFAOYSA-M
• SMILES: C1(OC(=O)N(C)C)C=CC=C([N+](C)(C)C)C=1.S([O-])(=O)(=O)OC
• CAS DataBase Reference: 51-60-5(CAS DataBase Reference)

Description and Uses

Neostigmine is a reversible inhibitor of acetylcholinesterase (AChE; K_d = 260 μM). In a rat model of knee joint inflammation, intrathecal administration of neostigmine (2-30 μg) increases endogenous acetylcholine levels and dose-dependently increases the latency of paw withdrawal in response to thermal and mechanical stimuli (ED₅₀s = 6.6 and 3.5 μg, respectively). Neostigmine (5 μg, i.p.) restores muscle action potentials in mice with a thymopoietin-induced neuromuscular block. Formulations containing neostigmine have been used in the treatment of myasthenia gravis and Ogilvie syndrome.

Cholinergic; miotic; antidote (curare)

Safety

• Symbol(GHS): GHS06,GHS08
• Signal word: Danger
• Hazard statements: H300-H315-H319-H334-H335
• Precautionary statements: P261-P284-P301+P330+P331+P310-P304+P340-P305+P351+P338-P342+P311
• Hazard Codes: T+
• Risk Statements: 28-36/37/38-42/43-26/27/28
• Safety Statements: 36-45-36/37/39-28A
• RIDADR: UN 2811 6.1/PG 2
• WGK Germany: 3
• RTECS: CY1225000
• HazardClass: 6.1(a)
• PackingGroup: II
• HS Code: 29242990
• Toxicity: LD50 in mice (mg/kg): 0.16 i.v.; 0.42 s.c.; 7.5 orally, (Randall, Lehmann)